Vol. 5 No. 4 (2025)
Reimbursement Reviews

Exagamglogene Autotemcel (Casgevy)

decorative image of the issue cover

Published April 7, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses exagamglogene autotemcel (Casgevy), Cell suspension in patient-specific vials, 4 to 13 × 106 cells/mL, for IV infusion.
  • Indication: For the treatment of patients 12 years of age and older with sickle cell disease with recurrent vaso-occlusive crises.